TY - JOUR
T1 - Effects of primary care C-reactive protein point-of-care testing on antibiotic prescribing by general practice staff
T2 - Pragmatic randomised controlled trial, England, 2016 and 2017
AU - Eley, Charlotte Victoria
AU - Sharma, Anita
AU - Lee, Hazel
AU - Charlett, Andre
AU - Owens, Rebecca
AU - McNulty, Cliodna
N1 - Funding Information:
Funding: The research was funded by PHE Primary Care Unit and the CRP POCTs were supplied by Alere Ltd at 50% of the price.
Publisher Copyright:
© 2020 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Background: C-reactive protein (CRP) testing can be used as a point-of-care test (POCT) to guide antibiotic use for acute cough. Aim: We wanted to determine feasibility and effect of introducing CRP POCT in general practices in an area with high antibiotic prescribing for patients with acute cough and to evaluate patients' views of the test. Methods: We used a McNulty-Zelen cluster pragmatic randomised controlled trial design in general practices in Northern England. Eight intervention practices accepted CRP testing and eight control practices maintained usual practice. Data collection included process evaluation, patient questionnaires, practice audit and antibiotic prescribing data. Results: Eight practices with over 47,000 patient population undertook 268 CRP tests over 6 months: 78% of patients had a CRP<20 mg/L, 20% CRP 20-100 mg/L and 2% CRP>100 mg/L, where 90%, 22% and 100%, respectively, followed National Institute for Health and Care Excellence (NICE) antibiotic prescribing guidance. Patients reported that CRP testing was comfortable (88%), convenient (84%), useful (92%) and explained well (85%). Patients believed CRP POCT aided clinical diagnosis, provided quick results and reduced unnecessary antibiotic use. Intervention practices had an estimated 21% reduction (95% confidence interval: 0.46-1.35) in the odds of prescribing for cough compared with the controls, a non-significant but clinically relevant reduction. Conclusions: In routine general practice, CRP POCT use was variable. Non-significant reductions in antibiotic prescribing may reflect small sample size due to non-use of tests. While CRP POCT may be useful, primary care staff need clearer CRP guidance and action planning according to NICE guidance.
AB - Background: C-reactive protein (CRP) testing can be used as a point-of-care test (POCT) to guide antibiotic use for acute cough. Aim: We wanted to determine feasibility and effect of introducing CRP POCT in general practices in an area with high antibiotic prescribing for patients with acute cough and to evaluate patients' views of the test. Methods: We used a McNulty-Zelen cluster pragmatic randomised controlled trial design in general practices in Northern England. Eight intervention practices accepted CRP testing and eight control practices maintained usual practice. Data collection included process evaluation, patient questionnaires, practice audit and antibiotic prescribing data. Results: Eight practices with over 47,000 patient population undertook 268 CRP tests over 6 months: 78% of patients had a CRP<20 mg/L, 20% CRP 20-100 mg/L and 2% CRP>100 mg/L, where 90%, 22% and 100%, respectively, followed National Institute for Health and Care Excellence (NICE) antibiotic prescribing guidance. Patients reported that CRP testing was comfortable (88%), convenient (84%), useful (92%) and explained well (85%). Patients believed CRP POCT aided clinical diagnosis, provided quick results and reduced unnecessary antibiotic use. Intervention practices had an estimated 21% reduction (95% confidence interval: 0.46-1.35) in the odds of prescribing for cough compared with the controls, a non-significant but clinically relevant reduction. Conclusions: In routine general practice, CRP POCT use was variable. Non-significant reductions in antibiotic prescribing may reflect small sample size due to non-use of tests. While CRP POCT may be useful, primary care staff need clearer CRP guidance and action planning according to NICE guidance.
UR - http://www.scopus.com/inward/record.url?scp=85095780844&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2020.25.44.1900408
DO - 10.2807/1560-7917.ES.2020.25.44.1900408
M3 - Article
C2 - 33153517
AN - SCOPUS:85095780844
SN - 1025-496X
VL - 25
JO - Eurosurveillance
JF - Eurosurveillance
IS - 44
M1 - 1900408
ER -